A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial) | Journal of Neurology, Neurosurgery & Psychiatry
To investigate whether oral administration of a standardised frankincense extract (SFE) is safe and reduces disease activity in patients with relapsing-remitting multiple sclerosis (RRMS).. To read the full article, log in using your NHS OpenAthens details.
